Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2021

Kerr Keith M, Bibeau Frédéric, Thunnissen Erik, Botling Johan, Ryška Aleš, Wolf Jürgen, Öhrling Katarina, Burdon Peter, Malapelle Umberto, Büttner Reinhard

Abstract excerpt

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC) targetable by small-molecule inhibitors, and the development of immunotherapies, have revolutionised NSCLC treatment. Today, instead of non-selective chemotherapies, all patients with advanced NSCLC eligible for treatment (and increasing numbers with earlier, less extensive disease) require fast and comprehensive screening of...

Topics

Asia
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Europe
Humans
Lung Neoplasms
Mutation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33690091
DOI: 10.1016/j.lungcan.2021.02.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.PMID 33690091Read ↗

The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.Semantic proximity Read ↗

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.Semantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Semantic proximity Read ↗

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.Semantic proximity Read ↗

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).Semantic proximity Read ↗

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung CancerSemantic proximity Read ↗

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Semantic proximity Read ↗

[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].Semantic proximity Read ↗

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Semantic proximity Read ↗

Prognostic and predictive biomarkers in non-small cell lung carcinoma.Semantic proximity Read ↗

Current and future trends in non-small cell lung cancer biomarker testing: The American experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.